ESTRO 2025 - Abstract Book

S923

Clinical - Haematology

ESTRO 2025

Toxicity data was available for 27/36 (75%) patients. There was no toxicity ≥ grade 2. 1 patient reported worsening xerostomia.

Conclusion: LDRT is an effective treatment for salivary MALT lymphoma. It produces durable local control and sites can be retreated with further response. LDRT is well tolerated and does not appear to cause significant xerostomia, even in patients with SS .

Keywords: Low dose radiotherapy, salivary, MALT

4617

Poster Discussion Single-Institution Experience: Total Marrow and Lymph Node Irradiation vs. Total Body Irradiation for Allogeneic Transplantation María Panizo Inogés 1 , José Juan Rifón Roca 1 , Sara Villar 1 , Adriana Martínez-Lage 2 , María Esperanza Rodríguez 2 1 hematology, Clínica Universidad de Navarra, Pamplona, Spain. 2 Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain Purpose/Objective: This study aimed to evaluate the outcomes of patients treated with low-dose TMLI, focusing on engraftment, full donor chimerism, and extrahematologic toxicities. The results were compared with those of a cohort receiving traditional TBI-based conditioning. To compare the efficacy and safety of both techniques in both adult and pediatric patients. Material/Methods: This prospective, single-center study included 36 patients with advanced hematologic malignancies who underwent allo-HPT. Between 2022 and 2024, the NMAC regimen consisted of cyclophosphamide, fludarabine, and low-dose TBI or TMLI (12 Gy/6 fx). Patients received post-transplantation cyclophosphamide, calcineurin inhibitor, and